Hexagon Nutrition IPO (₹553 Cr Market Cap): A Nutrition Player Lists at Full Price

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

Hexagon Nutrition comes to the market at ₹45 per share—a secondary IPO that raises nothing for the company, only for its selling shareholders. The 30.86 crore shares offered are entirely an exit play; not a rupee touches the balance sheet.

The numbers that matter: FY25 revenue was ₹331.29 crore, PAT ₹24.38 crore. Nine months into FY26 (Dec 31, 2025), the company has already booked ₹27.03 crore in profit on ₹275.57 crore in revenue—suggesting an annualized run-rate that overstates nothing and understates little.

The market prices this at 15.36x annualized FY26 earnings (post-IPO), or 22.73x FY25 reported earnings. Net worth sits at ₹223.05 crore (Dec 2025). Debt is ₹39.79 crore. The company has built itself from a 1993 micronutrient player into a three-segment business: B2C branded wellness, B2B premix formulations, and institutional ready-to-use foods.

The tension: a company that has been profitable for decades, growing both top and bottom lines, lands at a valuation that the market apparently considers fully priced—not cheap, not expensive, just there.

Does a PAT margin moving from 7.36% (FY25) to 9.81% (9M FY26) signal operational momentum, or merely a seasonal lift?

2. Introduction

Hexagon Nutrition incorporated in 1993, started as a micronutrient formulations supplier to FMCG companies, and has since climbed the value chain into branded consumer products and clinical nutrition.

The company operates three Indian manufacturing plants—Nasik (Maharashtra), Chennai (Tamil Nadu), and Thoothukudi (Tamil Nadu)—plus an international unit in Tashkent, Uzbekistan. Chennai and Thoothukudi sit in SEZ zones, a structural advantage for duty-free imports and port proximity.

Distribution spans 350+ non-exclusive domestic distributors (including 8 with multi-state reach), 160+ in-house sales staff, and a network covering retail pharmacies, hospital chains, e-commerce, and its own branded platforms: Pentasure, Obesigo, Pediagold, and Nutrone (launched FY24).

Internationally, the company ships to 75+ countries across Asia, Africa, Europe, and South America. Its footprint includes regional offices in South Africa, Uzbekistan, and Hong Kong.

Headcount as of March 31, 2026: 527 employees on payroll, plus 513 contract workers. R&D operates from in-house centers in Nasik and Chennai, staffed by 12 qualified professionals.

This IPO is a pure secondary offering—30.86 crore shares at ₹45 each, raising ₹138.87 crore for selling shareholders (mostly the Kelkar family, which holds 89.41% pre-listing). Post-listing, the family’s stake falls to 45.74%. No capital flows to the company.

3. Business Model: WTF Do They Even Do?

Hexagon Nutrition operates three distinct product streams, each serving different customer types.

Segment 1: Branded Wellness & Clinical Nutrition (B2C). The consumer-facing crown jewel. Pentasure targets adult nutritional supplementation (think protein shakes for the health-conscious). Obesigo addresses weight management. Pediagold is pediatric nutrition. Nutrone, the new kid, entered the general wellness space in FY24. These brands sit in retail pharmacies, hospitals, and online—margins are wider here because the company owns the brand equity and the customer relationship.

Segment 2: Premix Formulations (B2B2C). This is the bread-and-butter legacy business. Hexagon manufactures customized vitamin and mineral premixes for India’s leading FMCG companies and multinationals. Think: a detergent maker adds micronutrients to a bar soap, or a biscuit manufacturer fortifies flour. Hexagon supplies the micronutrient blend. This segment is high-volume, moderate-margin, and has the stickiness of a supplier locked into a customer’s supply chain.

Segment 3: Ready-to-Use Foods (RUFs) & Micronutrient Powders (MNPs). This is the ESG play. The company is one of India’s largest licensed suppliers of MNPs to UN programmes, feeding global food fortification initiatives and public health work. Lower margins, but the volume and the mandate give it durability. RUFs (fortified foods for malnourished populations) sit in the same space.

Distribution is omnichannel by necessity: brands need retail pharmacies and hospital endorsements and e-commerce presence and wholesale distributors feeding tier-2 towns. The company has built all four legs.

The model strength: three revenue streams mean one customer concentration crisis doesn’t crater the ship. The model weakness: three segments demand three separate sales, supply-chain, and brand-building playbooks. That’s overhead.

4. Financials Overview

Figures are consolidated, in ₹ crore.

The table masks an interesting story. Revenue for 9M FY26 is ₹275.57 crore—on an annualized basis, that’s ₹367.43 crore, a 10.9% jump over FY25’s ₹331.29 crore. But profits are ahead of that pace: 9M PAT of ₹27.03 crore annualizes to ₹36.04 crore, a 47.8% rise over FY25’s ₹24.38 crore.

This gap between revenue growth (10.9%) and profit growth (47.8%) points to margin expansion. PAT margin climbs from 7.36% (FY25) to 9.81% (9M FY26). EBITDA margin does the same: from 12.33% (FY25) to 14.03% (9M FY26).

Where is this margin improvement coming from? The company notes rising manufacturing efficiency, scale in the B2C branded business, and a healthier product mix—premium brands outpacing commodity premixes. Whether this pace holds across a full-year cycle (including potential seasonal dips in Q4) remains an open question.

EBITDA for 9M FY26 is ₹37.55 crore. Assuming a normalized full-year EBITDA of ₹50 crore (a modest interpolation), the company would trade at around 11x EBITDA at the IPO price—not cheap relative to mature nutrition businesses, not expensive either.

5. Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.